

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>Innate Immunotherapeutics Limited</b>
<b>ABN</b>	16 165 160 841

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	<b>Simon Earl Wilkinson</b>
<b>Date of last notice</b>	24 July 2017

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	
<b>Date of change</b>	31 August 2018
<b>No. of securities held prior to change</b>	<p>100,000 Options (post consolidation) Exercise Price A\$4.50 Expiry Date 5 November 2018</p> <p>175,000 Options (post consolidation) Exercise Price A\$4.00 Expiry Date 20 August 2019</p> <p>175,000 Options (post consolidation) Exercise Price A\$6.50 Expiry Date 31 August 2018</p>

---

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Class</b>	Options - Exercise Price A\$6.50 Expiry Date 31 August 2018  Options – Exercise Price A\$0.60 Expiry Date 31 March 2022
<b>Number acquired</b>	1,370,000 Options – Exercise Price A\$0.60 Expiry Date 31 March 2022
<b>Number disposed</b>	175,000 Options Exercise Price A\$6.50 Expiry Date 31 August 2018 – Expired – Not Exercised
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	175,000 Options Exercise Price A\$6.50 Expiry Date 31 August 2018 – Expired – Not Exercised.  1,370,000 Options Exercise Price A\$0.60 Expiry Date 31 March 2022 were issued for nil consideration in accordance with the terms of the Company's Employee Share Option Plan following the approval of shareholders at the Annual General Meeting held on 30 August 2018.
<b>No. of securities held after change</b>	100,000 Options - Exercise Price A\$4.50 Expiry Date 5 November 2018  175,000 Options Exercise Price A\$4.00 Expiry Date 20 August 2019  1,370,000 Options Exercise Price A\$0.60 Expiry Date 31 March 2022
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	175,000 Options Expired – Not Exercised: Exercise Price A\$6.50 Expiry Date 31 August 2018 and 1,370,000 Options granted following shareholder approval at AGM held 30 August 2018: Exercise Price A\$0.60 Expiry Date 31 March 2022

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	
<b>Interest after change</b>	

**Part 3 – +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	
<b>If prior written clearance was provided, on what date was this provided?</b>	

4 September 2018

---

+ See chapter 19 for defined terms.